You have full text access to this OnlineOpen article

Cancer

Cover image for Cancer

1 September 2004

Volume 101, Issue 5

Pages 879–1103

  1. A Note from History

    1. Top of page
    2. A Note from History
    3. Review Articles
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Original Article
    10. Original Articles
    11. Original Article
    12. Original Articles
    13. Original Article
    14. Original Articles
    15. Correspondence
    1. You have free access to this content
      Medieval pathfinders in surgical oncology (pages 879–882)

      Steven I. Hajdu

      Article first published online: 16 JUL 2004 | DOI: 10.1002/cncr.20458

      The author discusses 12 pioneer physician-surgeons and their attempts at practicing surgical oncology. Their lives spanned more than 1000 years during the Middle Ages, and they differed greatly with regard to their education and experience as well as ethnic and religious backgrounds. However, all of these pioneers made early landmark contributions related to the detection, diagnosis, and cancer.

  2. Review Articles

    1. Top of page
    2. A Note from History
    3. Review Articles
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Original Article
    10. Original Articles
    11. Original Article
    12. Original Articles
    13. Original Article
    14. Original Articles
    15. Correspondence
    1. You have full text access to this OnlineOpen article
      The role of fludarabine in the treatment of follicular and mantle cell lymphoma (pages 883–893)

      Georg Lenz, Wolfgang Hiddemann and Martin Dreyling

      Article first published online: 27 JUL 2004 | DOI: 10.1002/cncr.20483

      Fludarabine, the most widely used purine analog, exhibits a high level of activity in the treatment of advanced-stage follicular and mantle cell lymphoma, and it is particularly effective when used in combination with the monoclonal antibody rituximab. The current review summarizes existing knowledge regarding the clinical activity of and the toxicities associated with fludarabine in the treatment of these subtypes of lymphoma.

    2. You have full text access to this OnlineOpen article
      Prostate-specific antigen: A review of the validation of the most commonly used cancer biomarker (pages 894–904)

      Javier Hernández and Ian M. Thompson

      Article first published online: 2 JUL 2004 | DOI: 10.1002/cncr.20480

      A recent analysis from the Prostate Cancer Prevention Trial (PCPT) indicated that 15.2% of men with a prostate-specific antigen (PSA) level of < 4.0 ng/mL have prostate carcinoma, with approximately 14.9% of these patients having high-grade disease. In light of these new findings, the authors present a historic perspective regarding the evolution of PSA-based screening for prostate carcinoma as well as some thoughts regarding the discovery and clinical application of new biomarkers with the ultimate goal of improving the early detection of clinically significant prostate carcinoma.

  3. Original Articles

    1. Top of page
    2. A Note from History
    3. Review Articles
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Original Article
    10. Original Articles
    11. Original Article
    12. Original Articles
    13. Original Article
    14. Original Articles
    15. Correspondence
    1. Disease Site

      Breast Disease
      You have full text access to this OnlineOpen article
      Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution (pages 905–912)

      Mattia Intra, Nicole Rotmensz, Giuseppe Viale, Luigi Mariani, Bernardo Bonanni, Mauro G. Mastropasqua, Viviana Galimberti, Roberto Gennari, Paolo Veronesi, Marco Colleoni, Eleni Tousimis, Arianna Galli, Aron Goldhirsch and Umberto Veronesi

      Article first published online: 9 JUL 2004 | DOI: 10.1002/cncr.20452

      The higher incidence of lobular carcinoma associated with a slightly higher incidence of multifocality suggested that synchronous bilateral invasive breast carcinoma (SBIBC) represented a special entity of multicentric breast carcinoma with similar biologic characteristics of high hormone responsiveness. This particular hormonal environment influenced either the initiation and development of these lesions simultaneously and independently from the single or multi-clonal origin, either a less aggressive biological behavior compared with unilateral breast carcinomas.

    2. You have full text access to this OnlineOpen article
      Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma (pages 913–917)

      Erika Resetkova, Ana M. Gonzalez-Angulo, Nour Sneige, Timothy J. Mcdonnell, Aman U. Buzdar, Shu Wan Kau, Yuko Yamamura, James M. Reuben, Gabriel N. Hortobagyi and Massimo Cristofanilli

      Article first published online: 27 JUL 2004 | DOI: 10.1002/cncr.20465

      The authors retrospectively assessed expression levels of P53, MDM-2, and MUC-1 to evaluate potential correlations between these markers and pathologic response, time to progression (TTP), and overall survival (OS) in 19 patients with inflammatory breast carcinoma (IBC). After a median follow-up period of 46 months, patients with tumors that overexpressed P53 and did not express MUC-1 had a significantly shorter median TTP and a significantly shorter median OS compared with other patients. Thus, expression of P53 and MUC-1 may be predictive of treatment efficacy and outcome for patients with IBC.

    3. You have full text access to this OnlineOpen article
      Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors (pages 918–925)

      Roman Rouzier, Marie-Christine Mathieu, Lucas Sideris, Esther Youmsi, Radhika Rajan, Jean-Rémi Garbay, Fabrice André, Hugo Marsiglia, Marc Spielmann and Suzette Delaloge

      Article first published online: 23 JUL 2004 | DOI: 10.1002/cncr.20491

      In the current study, initial tumor diameter > 5 cm, low histologic grade, lobular histology, and multicentricity were independent predicting factors of breast conservation ineligibility after 3–4 courses of neoadjuvant anthracycline-based chemotherapy. When carefully selected, patients treated with breast conservation had a risk of local disease recurrence similar to the risk of chest wall disease recurrence after mastectomy.

    4. You have full text access to this OnlineOpen article
      Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events : Experience in patients undergoing prophylactic mastectomy (pages 926–933)

      Tari A. King, Archana Ganaraj, Jane V. Fey, Lee K. Tan, Clifford Hudis, Larry Norton, Hiram S. Cody III and Patrick I. Borgen

      Article first published online: 29 JUL 2004 | DOI: 10.1002/cncr.20517

      Cytokeratin-positive cells in sentinel lymph nodes are rare in the absence of cancer and do not appear to be the result of previous breast instrumentation. Although the prognostic significance of immunohistochemically-detected positive cells remains controversial, the current study suggests that they are not random events.

  4. Original Article

    1. Top of page
    2. A Note from History
    3. Review Articles
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Original Article
    10. Original Articles
    11. Original Article
    12. Original Articles
    13. Original Article
    14. Original Articles
    15. Correspondence
    1. Disease Site

      Endocrine Disease
      You have full text access to this OnlineOpen article
      A Phase II trial of gemcitabine for metastatic neuroendocrine tumors (pages 934–939)

      Matthew H. Kulke, Haesook Kim, Jeffrey W. Clark, Peter C. Enzinger, Thomas J. Lynch, Jeffrey A. Morgan, Michele Vincitore, Ann Michelini and Charles S. Fuchs

      Article first published online: 16 JUL 2004 | DOI: 10.1002/cncr.20466

      Eighteen patients with metastatic neuroendocrine tumors were treated with gemcitabine using a standard weekly schedule. No biochemical or radiologic responses were observed, demonstrating that gemcitabine was not an active agent in this disease.

  5. Original Articles

    1. Top of page
    2. A Note from History
    3. Review Articles
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Original Article
    10. Original Articles
    11. Original Article
    12. Original Articles
    13. Original Article
    14. Original Articles
    15. Correspondence
    1. Disease Site

      Gastrointestinal Tract
      You have full text access to this OnlineOpen article
      The accuracy of endoscopic ultrasound for restaging esophageal carcinoma after chemoradiation therapy (pages 940–947)

      Ishaan Kalha, Madhukar Kaw, Norio Fukami, Mihir Patel, Sandeep Singh, Harish Gagneja, Deborah Cohen and Jeffrey Morris

      Article first published online: 2 JUL 2004 | DOI: 10.1002/cncr.20429

      Endoscopic ultrasound (EUS) was not accurate for restaging esophageal adenocarcinoma after patients underwent chemoradiation when the standard TNM classification system was used.

    2. Genitourinary Disease
      You have full text access to this OnlineOpen article
      Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma (pages 948–956)

      Axel Heidenreich, Frank Sommer, Carsten H. Ohlmann, Andres J. Schrader, Peter Olbert, Joachim Goecke and Udo H. Engelmann

      Article first published online: 27 JUL 2004 | DOI: 10.1002/cncr.20455

      The administration of pegylated liposomal doxorubicin to patients with symptomatic hormone-refractory prostate carcinoma resulted in an objective decrease in prostate-specific antigen levels in 32% of all cases and in significant pain reduction in 54% of all cases. The median survival duration documented in the current study (13.4 months) was similar to the median survival durations that have been reported in trials involving mitoxantrone and taxanes.

    3. You have full text access to this OnlineOpen article
      Small cell carcinoma of the urinary bladder : A clinicopathologic analysis of 64 patients (pages 957–962)

      Liang Cheng, Chong-Xian Pan, Ximing J. Yang, Antonio Lopez-Beltran, Gregory T. MacLennan, Haiqun Lin, Timothy M. Kuzel, Veronica Papavero, Maria Tretiakova, Kelly Nigro, Michael O. Koch and John N. Eble

      Article first published online: 9 JUL 2004 | DOI: 10.1002/cncr.20456

      Patients with small cell carcinoma of the urinary bladder have a dismal prognosis. In this series of patients, the 1-year and 5-year disease-specific survival rates were 56% and 16%, respectively. Improvements in survival may depend on the identification of new molecular markers for use in early diagnosis and for novel targeted therapies.

    4. You have full text access to this OnlineOpen article
      The level of cadherin-6 mRNA in peripheral blood is associated with the site of metastasis and with the subsequent occurrence of metastases in renal cell carcinoma (pages 963–968)

      Toru Shimazui, Kazuhiro Yoshikawa, Hirotsugu Uemura, Yoshihiko Hirao, Shinsuke Saga and Hideyuki Akaza

      Article first published online: 29 JUL 2004 | DOI: 10.1002/cncr.20479

      The authors evaluated the significance of the presence of circulating renal cell carcinoma (RCC) cells in the development of metastases. Their findings indicated that the quantification of cadherin-6 mRNA in peripheral blood may be a significant predictive marker for current and future metastases in patients with RCC.

    5. Gynecologic Oncology
      You have full text access to this OnlineOpen article
      Efficacy of radiotherapy for ovarian ablation : Results of a Breast Intergroup study (pages 969–972)

      Lorie L. Hughes, Robert J. Gray, Lawrence J. Solin, Nicholas J. Robert, Silvana Martino, Debu Tripathy, James N. Ingle, William C. Wood, For the Eastern Cooperative Oncology Group, the Southwest Oncology Group, Cancer and Leukemia Group B and and The North Central Cancer Treatment Group

      Article first published online: 22 JUL 2004 | DOI: 10.1002/cncr.20481

      In 1994, the Eastern Cooperative Oncology Group initiated a randomized clinical trial for the Breast Intergroup in premenopausal patients with early-stage breast carcinoma in whom tamoxifen as adjuvant systemic therapy was compared with tamoxifen and ovarian ablation by one of three different methods. We report the efficacy of the radiotherapy regimen in this study to produce ovarian cancer.

    6. Head and Neck Disease
      You have full text access to this OnlineOpen article
      Tumor lymphangiogenesis in head and neck squamous cell carcinoma : A morphometric study with clinical correlations (pages 973–978)

      Alessandro Franchi, Oreste Gallo, Daniela Massi, Gianna Baroni and Marco Santucci

      Article first published online: 2 JUL 2004 | DOI: 10.1002/cncr.20454

      Tumor lymphangiogenesis as assessed using the monoclonal antibody D2-40 was found to be an indicator of the risk of lymph node metastasis in patients with squamous cell carcinoma of the head and neck.

    7. Hematologic Malignancies
      You have full text access to this OnlineOpen article
      Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation (pages 979–988)

      Daniela Cilloni, Francesca Messa, Enrico Gottardi, Milena Fava, Francesca Arruga, Ilaria Defilippi, Sonia Carturan, Emanuela Messa, Alessandro Morotti, Emilia Giugliano, Giovanna Rege-Cambrin, Daniele Alberti, Michele Baccarani and Giuseppe Saglio

      Article first published online: 23 JUL 2004 | DOI: 10.1002/cncr.20457

      The inhibition of Wilms tumor gene transcript levels after a short period of in vitro exposure of pretherapy bone marrow samples to imatinib was correlated with the inhibition of colony growth and may represent the basis for an easy test that is capable of predicting the sensitivity of patients with chronic myelogenous leukemia to treatment with imatinib.

  6. Original Article

    1. Top of page
    2. A Note from History
    3. Review Articles
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Original Article
    10. Original Articles
    11. Original Article
    12. Original Articles
    13. Original Article
    14. Original Articles
    15. Correspondence
    1. Disease Site

      Hematologic Malignancies
      You have full text access to this OnlineOpen article
      Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome (pages 989–998)

      Lee-Yung Shih, Tung-Liang Lin, Po-Nan Wang, Jin-Hou Wu, Po Dunn, Ming-Chung Kuo and Chein-Fuang Huang

      Article first published online: 12 JUL 2004 | DOI: 10.1002/cncr.20440

      The prognostic relevance of the fms-like tyrosine kinase 3 internal tandem duplication (FLT3/ITD) mutation was investigated in a large cohort of patients with myelodysplastic syndrome. The current study found that the FLT3/ITD mutation was associated with a high risk of transformation to acute myeloid leukemia (AML), rapid progression of AML, and poor survival in patients with myelodysplastic syndrome.

    2. You have full text access to this OnlineOpen article
      Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies (pages 999–1008)

      Maher Albitar, Kim-Anh Do, Marcella M. Johnson, Francis J. Giles, Iman Jilani, Susan O'Brien, Jorge Cortes, Deborah Thomas, Laura Z. Rassenti, Thomas J. Kipps, Hagop M. Kantarjian and Michael Keating

      Article first published online: 14 JUL 2004 | DOI: 10.1002/cncr.20477

      The data in the current study not only demonstrated that soluble CD52 (sCD52) was detectable and useful in the staging and monitoring of patients with chronic lymphocytic leukeima, but also showed that sCD52 formed immune complexes with alemtuzumab and may influence the efficacy and toxicity of alemtuzumab therapy.

  7. Original Articles

    1. Top of page
    2. A Note from History
    3. Review Articles
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Original Article
    10. Original Articles
    11. Original Article
    12. Original Articles
    13. Original Article
    14. Original Articles
    15. Correspondence
    1. Disease Site

      Hepatobiliary Disease
      You have full text access to this OnlineOpen article
      Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. (pages 1009–1017)

      Jian-Min Yuan, Sugantha Govindarajan, Kazuko Arakawa and Mimi C. Yu

      Article first published online: 7 JUL 2004 | DOI: 10.1002/cncr.20427

      In the current study, heavy alcohol consumption, diabetes, and hepatitis virus infection exerted independent and synergistic effects on risk of hepatocellular carcinoma in U.S. blacks and whites.

  8. Original Article

    1. Top of page
    2. A Note from History
    3. Review Articles
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Original Article
    10. Original Articles
    11. Original Article
    12. Original Articles
    13. Original Article
    14. Original Articles
    15. Correspondence
    1. Disease Site

      Neuro-Oncology
      You have full text access to this OnlineOpen article
      Differential expression of Csk homologous kinase (CHK) in normal brain and brain tumors (pages 1018–1027)

      Sun-Ok Kim, Shalom Avraham, Shuxian Jiang, Radoslaw Zagozdzon, Yigong Fu and Hava Karsenty Avraham

      Article first published online: 14 JUL 2004 | DOI: 10.1002/cncr.20442

      In the current study, the authors investigated the role of Csk homologous kinase (CHK) in normal neuronal development and differentiation, as well as during oncogenic transformation. They found that expression of CHK is both cell type specific and differentiation stage specific in the rat central nervous system. However, CHK expression is down-regulated in neuroblastoma and astrocytoma cell lines and in primary brain tumors, whereas Csk is highly expressed in these transformed cell lines.

  9. Original Articles

    1. Top of page
    2. A Note from History
    3. Review Articles
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Original Article
    10. Original Articles
    11. Original Article
    12. Original Articles
    13. Original Article
    14. Original Articles
    15. Correspondence
    1. Disease Site

      Neuro-Oncology
      You have full text access to this OnlineOpen article
      Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma : A long-term analysis (pages 1028–1035)

      Marko Ständer, Aurelia Peraud, Barbara Leroch and Friedrich W. Kreth

      Article first published online: 7 JUL 2004 | DOI: 10.1002/cncr.20432

      The authors retrospectively analyzed the prognostic impact of TP53 mutation status and P53 expression/accumulation on long-term outcome for adult patients with supratentorial World Health Organization (WHO) Grade II astrocytoma or oligoastrocytoma. Mutation of the TP53 gene is a common early event in the pathogenesis of supratentorial WHO Grade II astrocytoma or oligoastrocytoma, and the presence of such mutations was found to be an independent unfavorable predictor of overall survival, progression-free survival, and time to malignant transformation for patients in the current study.

    2. You have full text access to this OnlineOpen article
      Analysis of interleukin-13 receptor α2 expression in human pediatric brain tumors (pages 1036–1042)

      Mariko Kawakami, Koji Kawakami, Satoru Takahashi, Masato Abe and Raj K. Puri

      Article first published online: 22 JUL 2004 | DOI: 10.1002/cncr.20470

      The authors found that pediatric brain tumor specimens (including glioblastoma specimens) express the interleukin-13 receptor α2 (IL-13Rα2) chain and that this chain may serve as a molecular target for IL-13R–targeted treatment of malignant disease.

    3. Discipline

      Diagnostic Imaging
      You have full text access to this OnlineOpen article
      An academic health center cost analysis of screening mammography : Creating a financially viable service (pages 1043–1050)

      Steven L. Chen, Samuel Clark, Lori J. Pierce, Daniel F. Hayes, Mark A. Helvie, Paula L. Greeno, Lisa A. Newman and Alfred E. Chang

      Article first published online: 23 JUL 2004 | DOI: 10.1002/cncr.20476

      In the current reimbursement climate, screening mammography programs are unlikely to be financially viable unless they are run in the context of an integrated health system. In this context, targeting higher-risk populations can substantially improve the overall margin of a screening program.

  10. Original Article

    1. Top of page
    2. A Note from History
    3. Review Articles
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Original Article
    10. Original Articles
    11. Original Article
    12. Original Articles
    13. Original Article
    14. Original Articles
    15. Correspondence
    1. Discipline

      Epidemiology
      You have full text access to this OnlineOpen article
      Persistent area socioeconomic disparities in U.S. incidence of cervical cancer, mortality, stage, and survival, 1975–2000 (pages 1051–1057)

      Gopal K. Singh, Barry A. Miller, Benjamin F. Hankey and Brenda K. Edwards

      Article first published online: 26 JUL 2004 | DOI: 10.1002/cncr.20467

      Substantial socioeconomic gradients in both U.S. cervical carcinoma incidence and mortality rates were observed, with inequalities in cervical carcinoma persisting during 1975–2000 against a backdrop of declining rates. Residents of lower socioeconomic areas, regardless of race/ethnicity, had significantly higher cervical carcinoma incidence and mortality rates, and patients in lower socioeconomic census tracts had significantly higher rates of late-stage cancer diagnosis and lower rates of cancer survival.

  11. Original Articles

    1. Top of page
    2. A Note from History
    3. Review Articles
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Original Article
    10. Original Articles
    11. Original Article
    12. Original Articles
    13. Original Article
    14. Original Articles
    15. Correspondence
    1. Discipline

      Medical Oncology
      You have full text access to this OnlineOpen article
      Effect of vitamin B12, folate, and dietary supplements on breast carcinoma chemotherapy–induced mucositis and neutropenia (pages 1058–1064)

      Richard F. Branda, Shelly J. Naud, Elice M. Brooks, Zhuan Chen and Hyman Muss

      Article first published online: 22 JUL 2004 | DOI: 10.1002/cncr.20484

      In the current study, the decrease in neutrophil counts caused by chemotherapy was ameliorated by dietary supplementation with a multivitamin or vitamin E. In contrast, high serum folate levels were associated with the exacerbation of this decrease in neutrophil counts.

    2. Pathology
      You have full text access to this OnlineOpen article
      Hospital-to-hospital variation in lymph node detection after colorectal resection (pages 1065–1071)

      Eric A. Miller, John Woosley, Christopher F. Martin and Robert S. Sandler

      Article first published online: 9 JUL 2004 | DOI: 10.1002/cncr.20478

      Low-volume hospitals were more likely to recover fewer than seven lymph nodes and less likely to find positive lymph nodes after colorectal resection compared with high- and median-volume hospitals. The current study suggests that patients at low-volume hospitals may have their tumors pathologically understaged more frequently compared with patients at medium- and high-volume hospitals.

  12. Original Article

    1. Top of page
    2. A Note from History
    3. Review Articles
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Original Article
    10. Original Articles
    11. Original Article
    12. Original Articles
    13. Original Article
    14. Original Articles
    15. Correspondence
    1. Discipline

      Pediatric Oncology
      You have full text access to this OnlineOpen article
      Doxorubicin for favorable histology, Stage II–III Wilms tumor : Results from the National Wilms Tumor Studies (pages 1072–1080)

      Norman E. Breslow, San-San Ou, J. Bruce Beckwith, Gerald M. Haase, John A. Kalapurakal, Michael L. Ritchey, Robert C. Shamberger, Patrick R. M. Thomas, Giulio J. D'Angio and Daniel M. Green

      Article first published online: 16 JUL 2004 | DOI: 10.1002/cncr.20433

      The results of this historical comparison between the third and fourth National Wilms Tumor Studies, using both randomized and nonrandomized patients, strongly confirmed conclusions from randomized trials that triple-agent chemotherapy with doxorubicin lowered the risk of recurrence in patients with Stage III Wilms tumor of favorable histology. There remains a lack of conclusive evidence showing that routine use of doxorubicin as a frontline agent, rather than its occasional use for retrieval, improves patient survival.

    2. You have full text access to this OnlineOpen article
      High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification (pages 1081–1089)

      Anne Laprie, Jean Michon, Olivier Hartmann, Caroline Munzer, Marc-David Leclair, Carole Coze, Dominique Valteau-Couanet, Dominique Plantaz, Christian Carrie, Jean-Louis Habrand, Christophe Bergeron, Pascal Chastagner, Anne-Sophie Défachelles, Olivier Delattre, Valérie Combaret, Jean Bénard, Yves Pérel, Virginie Gandemer, Hervé Rubie and Neuroblastoma Study Group of the French Society of Pediatric Oncology

      Article first published online: 16 JUL 2004 | DOI: 10.1002/cncr.20453

      The authors compared the outcomes of two groups of children with localized neuroblastoma and MYCN amplification who received or did not receive postoperative high-dose chemotherapy (HDC) and stem cell rescue (SCR). The 6-year survival rate difference was highly significant between the group of children (n = 20 patients) who received conventional postoperative treatment (survival rate: 25% ± 10%) and the group of children (n = 12 patients) who received postoperative HDC, SCR, and radiotherapy (83% ± 10% survival; P = 0.004).

  13. Original Articles

    1. Top of page
    2. A Note from History
    3. Review Articles
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Original Article
    10. Original Articles
    11. Original Article
    12. Original Articles
    13. Original Article
    14. Original Articles
    15. Correspondence
    1. Discipline

      Symptom Control and Palliative Care
      You have full text access to this OnlineOpen article
      Quality of life and survival prediction in terminal cancer patients : A multicenter study (pages 1090–1098)

      Antonio Vigano, Nora Donaldson, Irene J. Higginson, Eduardo Bruera, Salaheddin Mahmud and Maria Suarez-Almazor

      Article first published online: 26 JUL 2004 | DOI: 10.1002/cncr.20472

      Health care professionals should focus on physical health-related, quality-of-life indicators, such as nausea/emesis, dyspnea, and weakness, to gather prognostic clues in patients with terminal cancer.

  14. Correspondence

    1. Top of page
    2. A Note from History
    3. Review Articles
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Original Article
    10. Original Articles
    11. Original Article
    12. Original Articles
    13. Original Article
    14. Original Articles
    15. Correspondence
    1. You have full text access to this OnlineOpen article
    2. You have full text access to this OnlineOpen article
      Author reply (page 1100)

      Richard J. Bleicher, Nora M. Hansen and Armando E. Giuliano

      Article first published online: 30 JUN 2004 | DOI: 10.1002/cncr.20463

    3. You have full text access to this OnlineOpen article
    4. You have full text access to this OnlineOpen article
      Author reply (page 1101)

      Mary Ann Weiser

      Article first published online: 2 JUL 2004 | DOI: 10.1002/cncr.20462

    5. You have full text access to this OnlineOpen article
    6. You have full text access to this OnlineOpen article
      Author reply (pages 1102–1103)

      Michael J. Morris, Howard I. Scher and Nicholas Sauter

      Article first published online: 16 JUL 2004 | DOI: 10.1002/cncr.20464

SEARCH

SEARCH BY CITATION